Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome

Daniel J. Lenihan, Alvaro J. Alencar, Deborah Yang, Razelle Kurzrock, Michael J. Keating, Madeleine Duvic

Research output: Contribution to journalArticlepeer-review

110 Scopus citations

Abstract

Alemtuzumab is a monoclonal antibody to CD52 that has activity in T-cell leukemia and lymphoma. This study aims to describe the complications and outcomes of a subset of patients with mycosis fungoides/Sézery syndrome who were treated with alemtuzumab. Four of 8 patients, with no prior history of cardiac problems, developed significant cardiac toxicity (congestive heart failure or arrhythmia) that mostly improved after alemtuzumab discontinuation. The role of this agent in potentially inducing important cardiac side effects is suggested and argues for further Investigation.

Original languageEnglish (US)
Pages (from-to)655-658
Number of pages4
JournalBlood
Volume104
Issue number3
DOIs
StatePublished - Aug 1 2004
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome'. Together they form a unique fingerprint.

Cite this